XML 113 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
OPERATING ACTIVITIES    
Segment net loss $ (24,526) $ (17,875)
Non-cash items:    
Depreciation 330 355
Loss on impairment of leasehold improvements and lab equipment 2,811 0
Stock-based compensation expense 3,564 2,014
Change in fair value of contingent consideration 299 180
Non-cash royalty revenue (448) (593)
Non-cash interest expense 28 36
Net accretion and amortization of investments in marketable securities (718) (553)
Net change in operating items:    
Accounts receivable 1,227 (363)
Prepaid expenses and other assets 413 (156)
Accounts payable and accrued liabilities 4,545 (2,024)
Change in deferred license revenue (812) (244)
Other liabilities (104) (72)
Net cash used in operating activities (13,391) (19,295)
INVESTING ACTIVITIES    
Purchase of investments in marketable securities (34,716) (25,397)
Disposition of investments in marketable securities 46,065 37,186
Acquisition of property and equipment 0 (95)
Net cash provided by investing activities 11,349 11,694
FINANCING ACTIVITIES    
Issuance of common shares pursuant to the Open Market Sale Agreement 0 21,765
Issuance of common shares pursuant to exercise of stock options 2,653 2,454
Issuance of common shares pursuant to ESPP 131 211
Net cash provided by financing activities 2,784 24,430
Effect of foreign exchange rate changes on cash and cash equivalents 4 (13)
Increase in cash and cash equivalents 746 16,816
Cash and cash equivalents, beginning of period 36,330 26,285
Cash and cash equivalents, end of period $ 37,076 $ 43,101